(EMAILWIRE.COM, November 23, 2018 ) Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
This market is boosted by the growing prevalence of diabetes and obesity, and high investments for research and development, which leads to rising demand for NASH and others nonalcoholic fatty liver diseases (NAFLD) therapies in the market. As per the regional analysis, the well-established healthcare infrastructure with the high adoption rate of new technologies and increasing research activities, makes North America dominate this market.
In 2017, the global Non-Alcoholic Steatohepatitis (NASH) Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.
This report focuses on the global Non-Alcoholic Steatohepatitis (NASH) Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non-Alcoholic Steatohepatitis (NASH) Drugs development in United States, Europe and China.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/2356596
The key players covered in this study
• AstraZeneca
• Conatus Pharmaceuticals
• Enzo Biochem
• Galmed Pharmaceuticals
• Genfit
• Gilead
• Horizon Pharma
• Immuron
• Intercept Pharmaceuticals
• Novo Nordisk
Market segment by Type, the product can be split into
• Vitamin E & Pioglitazone
• Obeticholic Acid (OCA)
• Elafibranor
• Selonsertib & Cenicriviroc
Market segment by Application, split into
• Hospital Pharmacy
• Online Provider
• Retail Pharmacy
Market segment by Regions/Countries, this report covers
• United States
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America
Browse the complete report @ http://www.orbisresearch.com/reports/index/global-non-alcoholic-steatohepatitis-nash-drugs-market-size-status-and-forecast-2018-2025
The study objectives of this report are:
• To analyze global Non-Alcoholic Steatohepatitis (NASH) Drugs status, future forecast, growth opportunity, key market and key players.
• To present the Non-Alcoholic Steatohepatitis (NASH) Drugs development in United States, Europe and China.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Non-Alcoholic Steatohepatitis (NASH) Drugs are as follows:
• History Year: 2013-2017
• Base Year: 2017
• Estimated Year: 2018
• Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Place a purchase order of this report @ http://www.orbisresearch.com/contact/purchase/2356596
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results